Endologix Remains on Track with Additional Device Enhancements, Expected Limited Market Introduction in Q2 2013
Endologix Inc. officials announce achievement of the CE (Conformite Europeenne) Mark of the current version of the Nellix EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms (AAA). Nellix is an innovative new endovascular aneurysm sealing (EVAS) system designed to simplify endovascular procedures, treat a broader range of patients, and provide enhanced clinical outcomes. The Nellix System is not approved in the United States for either investigational use or commercial sale.
Endologix is currently implementing a few enhancements to the Nellix System intended to optimize the device for commercialization. When complete, the Company will submit these enhancements to its Notified Body, with expectations of gaining CE Mark approval for the commercial version of the device and beginning a limited market introduction of the enhanced system in Europe by the end of the second quarter 2013.
John McDermott, president and CEO, Endologix, says, "Nellix has the potential to treat more AAA patients and get better clinical outcomes than any other device for the endovascular repair of AAA. Receiving CE Mark for the current version of the system is an important regulatory milestone and we look forward to providing this ground-breaking technology to physicians and their patients in 2013."